Thrombotic Risk Reduction and High Rate of Complete Molecular Response with the Long Term Use of Ropeg interferon Alpha-2b in Polycythemia Vera: Results from a Randomized Controlled Study, ASH 2019 interview with Dr. Kiladjian by David Wallace Dr. Jean Jacques Kiladjian, Professor of Clinical Hematology, Hopital Saint-Louis, Paris, France interviews with David Wallace, PV Reporter […]
Dr. Jean Jacques Kiladjian, ASH 2018: Ensayo RuxoPeg de fase I/II sobre la combinación de ruxolitinib y Pegasys en pacientes con mielofibrosis
RUXOPEG is the first study to formally assess the safety and efficacy of Rux + IFNa combination in MF patients never exposed to either drugs before First in ASH 2018 Series by David Wallace Dr Jean Jacques Kiladjian, Professor of Clinical Hematology, Hopital Saint-Louis, Paris, France interviews with David Wallace, PV Reporter at ASH 2018. […]
